Welcome to our dedicated page for Quoin Pharmaceuticals SEC filings (Ticker: QNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading biotech disclosures can feel like deciphering Latin—especially when Quoin Pharmaceuticals’ 10-K packs clinical-trial protocols, dilution tables, and licensing clauses into hundreds of pages. If you have ever asked, “Where can I get Quoin Pharmaceuticals SEC filings explained simply?” or searched for “Quoin Pharmaceuticals quarterly earnings report 10-Q filing,” you know the challenge.
Stock Titan solves it. Our AI parses every submission the instant it lands on EDGAR, transforming raw text into plain-language briefs, trend charts, and red-flag alerts. Want a snapshot of “Quoin Pharmaceuticals insider trading Form 4 transactions” or need “Quoin Pharmaceuticals Form 4 insider transactions real-time” before pivotal study data? One click delivers. Prefer a deeper dive? Our platform links each note in the “Quoin Pharmaceuticals annual report 10-K simplified” to the source paragraph, so you can verify numbers fast. We cover every form—10-Q revenue updates, 8-K trial readouts, S-3 capital raises, even the “Quoin Pharmaceuticals proxy statement executive compensation” sections that detail option grants.
What makes these filings worth tracking? Pipeline milestones, burn-rate disclosures, and “Quoin Pharmaceuticals 8-K material events explained” can shift valuation overnight. Our dashboards highlight upcoming catalysts, compare R&D spend quarter over quarter, and flag any “Quoin Pharmaceuticals earnings report filing analysis” that signals cash runway changes. Whether you’re monitoring “Quoin Pharmaceuticals executive stock transactions Form 4” for confidence signals or simply “understanding Quoin Pharmaceuticals SEC documents with AI,” Stock Titan delivers the clarity researchers, portfolio managers, and retail investors require—without wading through technical jargon.
Quoin Pharmaceuticals, Ltd. reported an initial beneficial ownership filing by Sally Bridget Lawlor, identifying her as Chief Financial Officer and a director. The filing reports ownership of 440 ADSs held directly; each ADS represents 35 ordinary shares. The transaction date triggering the filing is
Quoin Pharmaceuticals Ltd. filed an S-8 registration to register securities related to its employee benefit program. The filing incorporates the companys Form 10-K for the year ended December 31, 2024 and subsequent Form 10-Qs and Form 8-Ks through August 27, 2025. Exhibits include amended articles, a deposit agreement for ADSs, a 2025 Equity Incentive Plan (Exhibit 4.4), legal opinion and accountant consents. The filing supplies standard indemnification and insurance terms for officers and directors under Israeli law.
Quoin Pharmaceuticals reported the separation of an executive under a Separation Agreement that provides three key elements: a cash payment of $433,620 to be delivered in equal bi-weekly installments in lieu of 12 months' notice; a $108,405 bonus for the 2024 financial year to be paid in a lump sum on the one-year anniversary of the Separation Agreement's effective date; and an amendment to outstanding vested non-qualified stock options that extends the post-termination exercise window from 90 days to 1 year and 9 months. The filing is signed by Dr. Michael Myers, Chief Executive Officer, and includes an Inline XBRL cover page reference.
Quoin Pharmaceuticals Ltd. filed a Form S-8 to register securities for its American employee benefit plan. The submission references its Form 10-K for the year ended December 31, 2024, and subsequent Form 10-Qs and multiple Form 8-Ks filed between January and August 2025. The filing includes customary indemnification and insurance provisions for officers and directors, an exhibit list (legal opinion, auditor consent, power of attorney, filing fee table), and is signed by Dr. Michael Myers as CEO and authorized U.S. representative on August 25, 2025.
Quoin Pharmaceuticals director Natalie Ee Mun Leong reported an award of a share option on 08/21/2025 exercisable for 4,105 American Depositary Shares (ADSs) representing underlying ordinary shares. The option’s stated exercise price is $9.07 per ADS. The grant was approved by the Compensation Committee and Board on May 29, 2025 and was subsequently approved by shareholders on August 21, 2025. The option vests over four annual installments: 20% on each of May 29, 2026, 2027 and 2028, and 40% on May 29, 2029.
Anthony James Culverwell, a director of Quoin Pharmaceuticals, Ltd. (QNRX), was granted a stock option on 08/21/2025 covering 13,682 American Depositary Shares (ADSs) with an exercise price of $9.07 per ADS. Each ADS represents 35 ordinary shares, so the option covers the ADS-denominated equivalent of the underlying ordinary shares.
The option was approved by the Compensation Committee and Board on 05/29/2025 and became effective upon shareholder approval on 08/21/2025. The award vests over four annual installments: 20% vesting on each of 05/29/2026, 05/29/2027 and 05/29/2028, and 40% vesting on 05/29/2029. The reported ownership following the grant is 13,682 ADSs, held directly.
Quoin Pharmaceuticals, Ltd. (QNRX) director Dennis Langer was granted a share option to purchase 13,682 ADSs on August 21, 2025, as reported on Form 4 filed August 25, 2025. The option is stated in ADS terms with an exercise price of $9.07 per ADS; each ADS represents 35 ordinary shares. The grant was approved by the Compensation Committee and Board on May 29, 2025, subject to shareholder approval, and shareholders approved it on August 21, 2025. The option vests in four annual installments: 20% on each May 29 of 2026, 2027 and 2028, and 40% on May 29, 2029.
Quoin Pharmaceuticals Ltd. furnished a Form 8-K reporting corporate governance and personnel items. The filing lists several governance topics including the submission of matters to a vote of security holders, a material modification to rights of security holders, departures and elections of directors or certain officers, and compensatory arrangements for officers. The document discloses one specific executive term: Ms. Lawlor will be entitled to 28 days' annual leave in each calendar year (in addition to statutory public holidays). The Form 8-K was executed by the company's Chief Executive Officer.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
